{"title": "PDF", "author": "PDF", "url": "https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/K/Krebs/Krebsgeschehen_RKI.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "2016 zum November .............. 17 Krebs der Onkologie ............................ 84 D f\u00fcr 241 7.1 E inleitung und A ufgaben 260 weiteren Bundesl\u00e4ndern Krebsregistergesetze in Kraft. Das Krebsregistergesetz von 1995 bis 1999, das BKRG von 2009 und das Krebsfr\u00fcherkennungs- und Wohnort der Erkrankten, die von Koch-Institut (RKI) gegr\u00fcndet. Es hat die Aufgabe, die Daten Krebsregister Raten f\u00fcr den Zeitraum 2003 der Sterblichkeit in Deutschland 2011 durchge f\u00fchrten Zensus ergeben. vor allem bei in bei der Interpretation schen SEER-Programms (Surveillance, Epidemiology and End Results Program des National Cancer Institute) gelten international als diejenigen Register, die bereits F\u00e4r\u00f6er Inseln) und der urspr\u00fcnglichen 9 SEER Register (Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound und Utah) der der - ten der Europ\u00e4ischen Union (EU) wurde mittlere alter (Krankheitsfolgen). Nordrhein-Westfalen Neue Bundesl\u00e4nder/BerlinBayernBaden-W\u00fcrttemberg NiedersachsenHessenRheinland-PfalzSchleswig-HolsteinHamburgSaarlandBremen 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015Reg.-Bez. M\u00fcnster (148 sich in den 2,3 Anstieg der Mitgliedsstaaten Frauen bei uns etwas geringer als EU insgesamt. Da wohlha benden einem Anstieg der 5-Jahres-Pr\u00e4valenz of the Centers for Disease Control and Prevention (USA)Kapitel 2 of the Centers for Disease Cont-rol and Prevention bei den in Skandinavien wurde als NBL 5 5 - 64 J. NBL 65 - 74 J. NBL 75 J. u. \u00e4lter ABL 45 - 54 J. ABL 55 - 64 J. ABL 65 - 74 J. of the Centers for Disease Cont-rol and Prevention 2003 und ab 18% bis zum 50. Lebensjahr und 37% 2.5.a1 Einf\u00fchrung des Screeningprogramms (je nach Region vermehrt Tu Fr\u00fchstadium (in-situ und Stadium I) etwa ein Drittel die Sterberaten im g ruppen zwischen 55 und 74 wie Faktoren und - 69 J. Inzidenz 70 J. u. \u00e4lter Mortalit\u00e4t 30 - 49 J. Mortalit\u00e4t 50 - 69 altersstandardisierten Rate zwischen 2003 und u nter der Annahme ab Jahr 2012 hatte au\u00dferdem die US Preventive Services Task Force, ein von der US-Re - gierung - 74 J. Inzidenz 75 J. u. \u00e4lter Mortalit\u00e4t 45 - 59 J. Mortalit\u00e4t 60 - 74 Deutschland Skandinavien USA ist die altersstandardisierte Inzidenz in den letz - ten Myelosklerose m. 72 2.630 71 Burkitt-Lymphom/Leuk\u00e4mie 8 37 80 130 53 Marginalzonen-Lymphom 1 840 740 69 Reifzellige B-Zell Lymphome 400 67 Lymphoblastische/Vorl\u00e4uferzell-Lymphome/Leuk\u00e4mien B-Zell 140 154 80 110 26 T-Zell 18 48 30 80 25 o.n.A 53 64 150 140 23 of the Centers for Disease Control and Prevention (USA)Kapitel angestie - Jahren, Sterberaten \u00d6ster - reich niedriger als in Deutschland, w\u00e4hrend wurden, also vor der Ver\u00e4nderung Preven-tion Tumor, der seinen Ursprung von den farbgebenden Pigmentzellen der Aktuelle Situation und kurzfristige Sterblichkeit in USA nur bei in Skandinavien gesamten of the Nordic Disease Control and Prevention (USA) Abbildung 2.9.a6 Neuerkrankungsraten staaten und in ist, Jahren herausgebildet und ist vor allem auf die Entwicklung in der Altersgruppe von 45 bis 60 of the Nordic and Prevention Inzidenz 55 - 64 J. Inzidenz 65 - 74 J. Inzidenz 75 J. u. \u00e4lter Mortalit\u00e4t 45 - 54 J. Mortalit\u00e4t 55 - 64 J. Mortalit\u00e4t 65 - 74 J of the Nordic Disease Control and Prevention (USA) Abbildung 2.11.a5 Neuerkrankungsraten und der R\u00fcckgang in den j\u00fcngeren Altersgruppen etwas dagegen of the Centers for Disease Control and Prevention (USA)Kapitel 2 2013 M\u00e4nnern im Nordwesten und Th\u00fcringen und Hamburg fast Inzi - Leber unterschiedlichen of the Centers for Disease Control and Prevention (USA)Kapitel 2 1971, in jetzigen Form jedoch 74 /zero.lf/one.lf/two.lf/three.lf/four.lf/five.lf/six.lf/seven.lf/eight.lfj je e 1 10 00 0. .0 for Di-sease Control and Preven-tion Association of the Nordic Cancer Berlin 2. Kraywinkel K, Barnes B, Dahm et (2014) Daten Wiesbaden 4. Waterhouse J, Muir CS, Correa P et al. (1976) Cancer Incidence in Five Continents, Vol. III, IARC Sci Publ. IARC (Hrsg), Lyon, S p. 456 5. Eurostat (2015) Eurostat - Your key to European statistics. http://ec.europa.eu/eurostat/web/health/causes-death/data/database (Stand: 01.08.2016) 6. National Cancer Institute (2015) Joinpoint Regression Pro - gram Version 4.2.0 - April 2015; Statistical Methodology and Applications Branch, Surveillance Research Program. http://surveillance.cancer.gov/joinpoint . 7. Statistisches Pisani P, Bray F, Parkin DM (2002) Estimates of the wor - ld-wide prevalence of cancer for 25 sites in the adult popula - tion. Int J Cancer 97 (1): G, Ferlay J, Christensen N et al. (2016)NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 7.3. Association of the Nordic Cancer Registries. Danish Cancer Society. Available from http://www.ancr.nu , accessed on 01/08/2016. 11. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2015 Sub (1973-2013), National Cancer Institute, DCCPS, Surveillance Rese - arch Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission. Underlying mortality data provided by NCHS (www.cdc.gov/nchs). 12. Steliarova-Foucher E, O'Callaghan M, Forman D, Comber H, Bray F: European Cancer Observatory (2012) Cancer Incidence, Mortality, Prevalence and Survival in Europe. Version 1.0. European Network of Cancer Regis - tries, International Agency for Research on Cancer. Available from http://eco.iarc.fr, accessed on 01/08/2016. 13. Esserman LJ, Thompson IM, Jr., Reid B (2013) Overdiagnosis and overtreatment in cancer: an opportunity for impro - vement. JAMA 310 (8): 797-798 14. World Health Organisation (2016) of Diseases Revision News. http://www.who.int/classifications/ im Detail - Krebs gesamt 2009 bis 2014, Deutsch land, 17. Kaatsch P, Spix C, German Childhood Cancer Registry (2015) Annual Report (1980-2014). Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI) at the University Medical Center of the Johannes Gutenberg University Mainz 18. Statistisches Bundesamt erstattung des Bundes. RKI, Berlin 21. Weiss W, Homoncik M (2008) Colon cancer screening in Austria - Update 2008. J Gastroenterol Hepatol Erkr 6 (2): 23. Brenner H, Hoffmeister M, Stegmaier C et al. (2007) Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840,149 screening colonos - copies. Gut 56 (11): 1585-1589 24. Stock C, Ihle P, Sieg A et al. (2013) Adverse events requiring hospitalization within 30 days after outpatient screening and nonscreening colonoscopies. Gastrointest 47 (11): 1132-1136 26. 27. Devesa SS, Bray F, Vizcaino AP et al. (2005) International lung cancer trends by histologic type: male:female diffe - rences diminishing and adenocarcinoma rates rising. Int J Cancer 117 (2): 294-299 28. Lewis DR, Check DP, Caporaso NE et al. (2014) US lung cancer trends by histologic type. Cancer 120 (18): 2883-2892 29. Samet JM, Avila-Tang E, Boffetta P et al. (2009) Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res 15 (18): 5626-5645 30. Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6 (6): 229-239 31. KA, Patel DP, Hanson HA et al. (2016) Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score. Cancer Med 5 (1): 136-141 33. Li J, Berkowitz Z, Hall IJ (2015) Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations. J Am Board Fam Med 28 (4): 491-493 34. Barocas DA, Mallin K, Graves AJ et al. (2015) Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States. J Urol 194 (6): 1587-1593 35. Potosky AL, Kessler L, Gridley G et al. (1990) Rise in pro - static cancer incidence associated with increased use of transurethral resection. J Natl Cancer CK, Check DP, Lortet-Tieulent J et al. (2016) Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group. Int J Cancer 138 (6): 1388-1400 37. Spix C, Eletr D, Blettner M et al. (2008) Temporal trends in the incidence rate of childhood cancer in Germany 1987-2004. Int J Cancer 122 (8): 1859-1867 38. Kaatsch P, Mergenthaler A (2008) Incidence, time trends and regional variation of childhood leukaemia in Germany and Europe. Radiat Prot Dosimetry Kaatsch P, Steliarova-Foucher E, Crocetti E et al. (2006) Time trends of cancer incidence in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 42 (13): 1961-1971 40. Hrusak O, Trka J, Zuna J et al. (2002) Acute lymphoblastic leukemia incidence during socioeconomic transition: selec - tive increase in children from 1 to 4 years. Leukemia 16 (4): 720-725 41. McNally RJ, Cairns DP, Eden OB et al. (2001) Examination of temporal trends in the incidence of childhood leukaemias and lymphomas provides aetiological clues. Leukemia 15 (10): 1612-1618 42. McNally RJ, Roman E, Cartwright RA (1999) Leukemias and lymphomas: time trends in the UK, 1984-93. Cancer Causes Control 10 (1): 35-42 43. Shah A, Coleman MP (2007) Increasing incidence of child - hood leukaemia: a controversy re-examined. Br J Cancer 97 (7): 1009-1012 44. Babjuk M, B\u00f6hle A, Comperat E et al. (2015) Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS). Euro - pean Association of Urology 45. Van Hemelrijck MJJ, Michaud DS, Connolly GN et al. (2009) Tobacco use and bladder cancer patterns in three western European countries. J Public Health-Uk 31 (3): 335-344 46. Skov T, Sprogel P, Engholm G et al. (1991) Cancer of the lung and urinary bladder in Denmark, 1943-87: a cohort analysis. Cancer Causes Control 2 (6): 365-369 47. Erdmann F, Lortet-Tieulent J, Schuz J et al. (2013) Inter - national trends in the incidence of malignant melanoma 1953-2008--are recent generations at higher or lower risk? Int J Cancer 132 (2): 385-400 48. Lipsker D, Engel F, Cribier B et al. (2007) Trends in mela - noma epidemiology suggest three different types of mela - noma. Br J Dermatol L, Snijders PJF et al. (2012) Human papillomavirus and diseases of the upper airway: Head and neck cancer and respiratory papillomatosis. Vaccine 30 (SUPPL.5): F34-F54 50. Marur S, D'Souza G, Westra WH et al. (2010) HPV-associa - ted head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11 (8): 781-78951. Meyer C, Rumpf HJ, Hapke Neuland, Geesthacht 53. World Cancer Reserach Fund, American Institute for Cancer Research (2007) Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective, AICR, Washing - ton DC 54. Key TJ, Allen NE, Spencer EA et al. (2002) The effect of diet on risk of cancer. Lancet 360 (9336): 861-868 55. International Agency for Research on Cancer (Hrsg) (2012) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. A Review of Human Carcinogens. Part B: Biolo - gical Agents. Volume Lyon 56. Fischbach W, Malfertheiner P, Lynen Taylor-Robinson SD, Toledano MB et al. (2002) Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37 (6): 806-813 58. McGlynn KA, Tsao L, Hsing AW et al. (2001) International trends and patterns of primary liver cancer. Int J Cancer 94 (2): 290-296 59. El-Serag HB (2011) Hepatocellular 62. The global burden. Nature 488 (7413): S2-S3 63. Ferlay J, Soerjomataram I, Ervik M et al. (2016) GLOBOCAN 2012 v1.0, Cancer Incidence Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: http:// globocan.iarc.fr, accessed Die Verbesserung der wendung die Ber\u00fccksichtigung von Leitlinien bei Behandlung fest [ der in European Society of Medical Oncology und die European Clinical Oncology (ASCO) sowie das National Comprehensive Cancer Net - work (NCCN) aus den USA. Um die internationale Zusammenarbeit bei der - nienentwicklung und Implementierung zu unterst\u00fctzen, H\u00e4matologen und dem Inkrafttreten H\u00e4matologen und onk ologen f\u00fcr Pflegepersonal in von Menschen mit Krebs 89 3.2 ist ein fl\u00e4chendeckendes, bundesweites und bev\u00f6lkerungsbezogenes Krebsregister. Biometrie, der die Jugendalter f\u00fcr die ermittelt, f\u00fcr und damit dem auf Brustkrebs. Bei M\u00e4nnern war Lungenkrebs die Prostatakrebs die h\u00e4ufigste Diagnose im vertrags\u00e4rztlichen Bereich und in der Rehabilitation. Zwischen 2008 und 2013 ist die Zahl der - - - - - - - - - Geb\u00e4rmutterhals C53 - - - - - Geb\u00e4rmutterk\u00f6rper C54-C55 - - - - - Eierst\u00f6cke C56 aus - liativversorgung in das im Dezember 2015 in Kraft getreten wird der Ausbau Im Stress, Depressivit\u00e4t und weiteren emotionalen den Fallzahlen der gab f\u00e4lle kamen im Jahr 2013 Frauen etwa 30 Rehabilitationsf\u00e4lle weitere Gemeinsamkeit 1947 waren im Jahr 2013 66 bis 68 Jahre alt. Unterschiede der in den unter allen Rehabilitationen M\u00e4nnern. gr\u00f6\u00dfte versorgt, es 85 Jahren Jahr der Jahr der Versorgten den Jahren 2008 bis 2013 Einf\u00fchrung der diagnosebezo - genen Fallgruppen (Diagnosis 2000 mit 186 ist Abrechnungsverfahren mit Betten. ist R\u00fcckgang von 16,8% bei Frauen - schlechterverh\u00e4ltnissen der Statistisches Bun-desamt 2000 2008 von Sollvorgaben - men Audits zwischen und Union Against Cancer (UICC) eine internationale o rganisation, die bis Stadium IV, manchmal mit Unterteilungen siebten Auflage Inanspruchnahme Union Against Cancer (UICC) eine internationale or ganisation, die bis Stadium IV, manchmal mit Unterteilungen siebten Auflage die die GKV-Versicherte zwi - schen 2008 und 2013 stark zugenommen. Der Anstieg bei den M\u00e4nnern von 183 mit Dia Lungenkrebs im Jahr 2013 knapp doppelt so [ 19]. den GKV-Versicherten mit der Diag - Jahr wur 29,4% von 85 im Jahr 2000 auf 110 F\u00e4lle je 100.000 Einwohner 2013. Die - standardisierte Inanspruchnahme sank bei den M\u00e4nnern um 24,5% der Fallzahlen bei den Frauen Faktoren hin, 2013 mit der CD- 10 C33-C34), nach Al [ 19]. den GKV-Versicherten mit der Diag - Jahr wur 29,4% von 85 im Jahr 2000 auf 110 F\u00e4lle je 100.000 Einwohner 2013. Die - standardisierte Inanspruchnahme sank bei den M\u00e4nnern um 24,5% der Fallzahlen bei den Frauen CD- 10 C33-C34), nach Al Ein den allen Krankenhausf\u00e4llen der Diagnose Lungenkrebs betrug 2013 bei den in Vorsorge- den M\u00e4nnern. Die Entwicklung der Fallzah - len \u00e4hnelt dem Trend Statistisches Bun-desamt 2000 2008 empfiehlt Lungenkrebs von den M\u00e4nnern. Die Entwicklung der Fallzah - len \u00e4hnelt dem Trend weicht. Der Anteil der Rehabilitationsf\u00e4lle ist in den Altersgruppen von bis (bei M\u00e4nnern weicht. Der Anteil der Rehabilitationsf\u00e4lle ist in den Altersgruppen von bis (bei M\u00e4nnern ist dies ein 2008 Alter von 65 Jahren, bei M\u00e4nnern erst 2009 von 110 auf 113 je 100.000 GKV-Versicherte an. Bis 2013 sank die altersstandardi - stieg die Inanspruch - nahme in Bundesvereinigung 2008 2013 pen und Geschlecht, 20 ist dies ein 2008 Alter von 65 Jahren, bei M\u00e4nnern erst 2009 von 110 auf 113 je 100.000 GKV-Versicherte an. Bis 2013 sank die altersstandardi - stieg die Inanspruch - nahme in Bundesvereinigung 2008 2013 pen und Geschlecht, 20 ist f\u00e4lle bei Frauen mit Gipfel im Jahre 2010 ist 2013 Statistisches Bundesamt 2000 2008 ist f\u00e4lle bei Frauen mit Gipfel im Jahre 2010 ist 2013 Statistisches Bundesamt 2000 2008 der durch 0 bis unter 45 Jahren im Alter ab 80 Einwohner in den Jahren 2007 und 2008 in den 60 rehabilitativen - fel der je Einwohner, vor 0 bis unter 45 Jahren im Alter ab 80 gegen\u00fcber In der ist - dardisierte Inanspruchnahme je Zeitraum Vorsorge- Rehabilitationseinrichtungen mit bis 2008 gestiegen und danach bis 2013 zur\u00fcckgegangen.KERNAUSSAGEN Seit 2000 ist die der - der 2 008 10 C61), gegen\u00fcber In der ist - dardisierte Inanspruchnahme je Zeitraum Vorsorge- Rehabilitationseinrichtungen mit bis 2008 gestiegen und danach bis 2013 zur\u00fcckgegangen.KERNAUSSAGEN Seit 2000 ist die der - der 2 008 10 C61), 2013 weniger Rehabilitationsf\u00e4lle je Einwohner als 2003. Ab dem Alter von medikament\u00f6se an ( Ta- 3.3.t14 ). Ab Die 2013 Versorgung es die Alters - gruppe von 75 bis unter 80 Jahre. diagnos - in der station\u00e4ren 130 Literatur 1. Sackett DL, Rosenberg WM, Gray JA et al. (1996) Evidence based medicine: what it is and what it isn't. BMJ (Clinical research ed) 312 (7023): 71-72 K\u00f6tter T, Schaefer Blozik E et al. (2011) Die Entwicklung von in Onkologie. berg H, Baumann ment 16. Februar 2012, zuletzt ge\u00e4ndert am 20. November in Kraft am Januar 2015, Thomas RE, MacLennan G et al. (2004) Effectiveness and efficiency of guideline dissemination and implementation strategies. Health technology assessment (Winchester, England) 8 (6): iii-iv, 1-72 12. Bucker B, Schnee M et al. (2006) German ambulatory care physicians' perspectives on clinical guide - lines - a national survey. BMC family practice 7: 47 15. 19. Goeckenjan H, M (2010) Pr\u00e4vention, Diagnostik, Therapie und EONS (2013) Cancer Nursing Curriculum 2013. European Oncology Nursing Society (EONS), Br\u00fcssel 30. Deutsche Krankenhausgesellschaft (2011) Gesundheit in Deutsch - land. Gesundheitsberichterstattung des Bundes. Gemein - sam getragen von RKI und Destatis. RKI, 39. Deutsche Krebsgesellschaft e.V. (2015) Jahresbericht schaft, Deutsche Krebshilfe 45. Wessels T, Korsuk\u00e9witz C, Fischer et (2008) Medical Issues in Cancer Survi - vors\u2014A Review. The Cancer Journal 14 (6): 375-387 Weis zeit\u00fcberlebenden. H et al. (2014) Four-Week Pre - valence of Mental Disorders in Patients With Cancer Across Major Tumor Entities. Journal of Clinical Oncology 56. Pottins I, Irle H, Korsukewitz C (2009) Deutsche 59. Mehnert A, de Boer A, Feuerstein M (2013) Employment challenges for cancer survivors. Cancer zin. Schattauer, Stuttgart, S 1-11 62. Weltgesundheitsorganisation (2002) WHO Definition of Pal - V., Bundes\u00e4rztekammer (Hrsg), Berlin 65. Cremer-Schaeffer P, Radbruch L (2012) Palliative care in the light of legal and regulatory requirements in Germany. Bundesgesundheitsbla 55 (2): 231-237 66. Lindena G (2014) HOPE (Hrsg) 68. E, Thomas D B, Kopetsch T, Schmitz H (2013) What accounts for the regional differences in the utilisation of hospitals in Germany? Eur J Health Econ 14 (4): 615-627 79. G\u00f6pffarth D, Kopetsch T, Schmitz H (2015) Determinants of Regional Variation in Health Expenditures in Germany. Health Economics 25 (7): 801-815 80. Schulz M, Czihal T, Kopetsch T (2015) The impact of office-ba - sed care on hospitalizations for ambulatory care sensitive conditions. Eur J Health Econ 16 (4): 365-375 82. Giersiepen K, Heitmann krebs, Gesundheitsberichterstattung des Bundes. Robert Koch-Institut Berlin 83. F\u00fcrstenberg T, Laschat M, K et al. Tumoren. & Sons, Ltd., Weinheim 87. McDonald JR, Renehan AG, O'Dwyer ST et al. (2012) Lymph node harvest in colon and rectal cancer: Current considera - tions. World 89. Robinson LA, Ruckdeschel JC, Wagner H, Jr. et al. (2007) Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (3 Suppl): 243S-265S 90. Merk J, 91. Wienecke A, Barnes B, Lampert T et al. (2014) Changes in cancer incidence attributable to tobacco smoking in Germany, 1999-2008. International journal of cancer Journal international du cancer 134 (3): 682-691 92. Lampert T (2011) HW et al. (2013) Effect of mammography screening on surgical treatment for breast cancer: a nationwide analysis of hospitalization rates in Germany 2005-2009. Eur J Epidemiol 28 (8): 689-69698. Starker 4 stehen - je nach 2010, die in 791 54.081 34 3.088 208.441 17 2.228 157.821 51 3.055 264.400 - - - - Prostata C61 - - - - ICD-10: International Statistical Classification of 791 54.081 34 3.088 208.441 17 2.228 157.821 51 3.055 264.400 - - - - Prostata C61 - - - - ICD-10: International Statistical Classification of Diseases sank Experten der for Research and Treatment of Cancer (EORTC) Frageb\u00f6gen f\u00fcr die Erfassung der Bei M\u00e4nnern sowohl den AU-F\u00e4l 4,6% 2008 5,3%. Bei M\u00e4nnern ist er von 6,1% im Jahr 2002 Statistisches BundesamtFrauen M\u00e4nner 2002 2004 0 - 14 Jahre 71 83 97 82 83 107 99 88 15 - 29 Jahre 93 101 94 108 108 120 114 124 30 - 44 Jahre 501 516 539 484 300 317 314 Anteil der - krankungen als Diagnose In der Altersgruppe bis 65 Jahre betrug 24,2%, in Dabei unterscheiden 66-80 ist III und (RS5) RS5 Beeintr\u00e4chtigungen in und 2003 auf knapp 1000 an. Zwischen 2003 und 2013 ist der Trend jedoch 34,2% Rektums Neubildung des Rektums 4 12 4 28Tabelle Frauen bei 20,8% Jahr 1998 war die Rate bei M\u00e4nnern etwa 3-mal so hoch wie bei Patientinnen und Patienten, die um weniger 1 Prozent und 2009) bei Frauen zwischen 50 (um 3,7 der Ent Fragebogens der European 2 Milliarden Euro. Gegen\u00fcber 2002 ist dies der bis II - einen 100.000 Einwohner bei der Frauen. sich die Rate bei den Frauen nicht ver\u00e4ndert. Bei den sank Wiederauftre - vor die European - und bei 263 Millionen Euro. Gegen\u00fcber 2002 (2013) Lebensqualit\u00e4t von V, Merx H, Stegmaier C et al. (2004) Quality of life in patients with colorectal cancer 1 year after diagnosis compa - red with the general population: a population-based study. Clin et al. (2004) Age-specific detri - ments to quality of life among breast cancer patients one year after diagnosis. Eur J Cancer 40 (5): 673-680 9. Livingstone E, Krajewski C, Eigentler TK et al. (2015) Pro - spective evaluation of follow-up in melanoma patients in Germany - Results of a multicentre and longitudinal study. European Journal of Cancer 51 (5): 653-667 10. Beutel ME, Fischbeck S, Binder H et al. (2015) Depression, anxiety and quality of life in long-term survivors of malignant melanoma: a register-based cohort study. PLoS One 10 (1): e0116440 11. Waldmann A, Nolte S, Pritzkuleit R et al. (2011) Different aspects of self-reported quality of life in 450 german mela - noma survivors. Cancers (Basel) 3 (2): 2316-2332 12. Jansen L, Castro FA, Gondos A et al. (2015) Recent cancer survival in Germany: an analysis of common and less common cancers. International journal of cancer Journal international du cancer 136 (11): 2649-2658 13. Jansen L, Eberle A, Emrich K et al. (2014) Socioeconomic deprivation and cancer survival in Germany: an ecological analysis in 200 districts in Germany. International journal of cancer Journal international du cancer 134 (12): 2951-2960 14. Woods LM, Rachet B, Coleman MP (2006) Origins of socio-economic inequalities in cancer survival: a review. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 17 (1): 5-19 15. Nennecke A, Geiss K, Hentschel S et al. (2014) Survival of cancer patients in urban and rural areas of Germany--a comparison. Cancer Epidemiol 38 (3): 259-265 16. Jansen L, Gondos A, Eberle A et al. (2012) Cancer survival in Eastern and Western Germany after the fall of the iron curtain. Eur J Epidemiol 27 (9): 689-693 17. Sch\u00f6n D, Bertz J, \u00dcberlebensraten Krebspatienten in Deutschland. Robert Koch-Institut (Hrsg), Berlin 18. Baili P, Di Salvo F, Marcos-Gragera R et al. (2015) Age and case mix-standardised survival for all cancer patients in Europe 1999-2007: Results of EUROCARE-5, a populati - on-based study. Eur J Cancer 51 (15): 2120-2129 19. De Angelis R, Sant M, Coleman MP et al. (2014) Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. lancet 15 (1): 23-34 20. Gatta G, Botta L, Rossi S et al. (2014) Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5--a population-based study. The lancet oncology 15 (1): 35-4721. Allemani C, Weir HK, Carreira H et al. (2015) Global surveil - lance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385 (9972): 977-1010 22. The WHOQOL group (1995) The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 41 (10): 1403-1409 23. Radoschewski M Oransky (2007) Ralph S Paffenbarger Jr. The Lancet 370 (9587): 560 25. World Health Organization (1998) WHOQOL User Manual. Division of Mental Health and Prevention of Substance Abuse, World Health Organization (Hrsg), Geneva 26. Angermeyer MC, Kilian R, Matschinger - BREF: von Lebensqualit\u00e4t. Hogrefe, G\u00f6ttingen 27. Institute of Medicine, National Research Council (2005) The Medical and Psychological Concerns of Cancer Survivors After Treatment. In: Hewitt M, Greenfield S, Stoval E (Hrsg) From Cancer Patient to Cancer Survivor. The National Aca - demies Press, Washington, D.C. 28. Koch-Gallenkamp L, Bertram H, Eberle A et al. (2016) Fear of Recurrence in Long-Term Cancer Survivors-Do Cancer Type, Sex, Time Since Diagnosis, and Social Support Matter? Health Psychol 29. Hofmeister D, Singer S (2013) Die Lebensqualit\u00e4tsfrageb\u00f6 - gen der European Organisation for Research and Treatment of Cancer (EORTC). Aktuelle Entwicklungen. Bergman B et al. (1993) The Eu - ropean Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (5): 365-376 31. Johnson C, Aaronson N, Blazeby JM et al. (2011) Guidelines for Developing Questionnaire Modules. European Organi - sation for Research and Treatment of Cancer (Hrsg)Fourth Edition, Brussels 32. Leitlinienprogramm Onkologie (2014) (Hrsg) 33. of survival: reflections of a physi - cian with cancer. The New England journal of medicine 313 (4): 270-273 34. Jansen L, Herrmann A, Stegmaier C et al. (2011) Health-re - lated quality of life during the 10 years after diagnosis of colorectal cancer: a population-based study. Klinkhammer-Schalke M, Koller M, Steinger B et al. (2012) Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer. Br J Cancer 106 (5): 826-838 36. Gon\u00e7alves Bradley DC, Gibbons C, Ricci-Cabello I et al. (2015) Routine provision of information on patient-reported outcome measures to healthcare providers and patients in clinical practice (Protocol). Cochrane Database Syst Rev (4) 37. Brucker U, von Krebserkrankungen 170 38. Khan NF, Mant D, Carpenter L et al. (2011) Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study. Br J Cancer 105 Suppl 1: S29-37 39. Whistance RN, Conroy T, Chie W validation of the EORTC QLQ-CR29 questi - onnaire module to assess health-related quality of life in pa - tients with colorectal cancer. Eur J Cancer 45 (17): 3017-3026 40. Jansen L, Koch L, Brenner H et al. (2010) Quality of life among long-term (>= 5 years) colorectal cancer survivors - Systematic review. European Journal of Cancer 46 (16): 2879-2888 41. Krouse RS, Herrinton LJ, Grant M et al. (2009) Health-rela - ted quality of life among long-term rectal cancer survivors with an ostomy: manifestations by sex. J Clin Oncol 27 (28): 4664-4670 42. Pachler J, Wille-Jorgensen P (2012) Quality of life after rectal resection for cancer, with or without permanent colostomy. Cochrane Database Syst Rev 12: CD004323 43. Schwarz R, Hinz A (2001) Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 37 (11): 1345-1351 44. Hinz A, Singer S, Brahler E (2014) European reference values for the quality of life questionnaire EORTC QLQ-C30: Results of a German investigation and a summarizing analysis of six European general population normative studies. Acta Oncol 53 (7): AWMF (Hrsg), Berlin 46. Zeissig SR, Singer S, Koch L et al. (2015) [Utilisation of Psy - cho-oncological Services in Hospitals and Outpatient Coun - selling Centres by Survivors of Breast, Colon and Prostate Cancer]. Psychother Psychosom Med zertifizierten Darmkrebszentren, Berlin 48. Goeckenjan G, Sitter H, Thomas M et al. (2010) [Prevention, diagnosis, therapy, and follow-up of lung cancer]. Pneumolo - 49. Bergman NK, Ahmedzai S et al. (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 30A (5): 635-642 50. Schulte T, Schniewind B, Dohrmann P et al. (2009) The extent of lung parenchyma resection significantly impacts long-term quality of life in patients with non-small cell lung cancer. Chest 135 (2): 322-329 51. Schulte T, Schniewind B, Walter J et al. (2010) Age-related impairment of quality of life after lung resection for non-small cell lung cancer. Lung Cancer 68 (1): 115-120 52. Fuchs TR MA, Schwartz CE (1999) Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med 48 (11): 1507-1515 54. Dimeo FC, Thomas F, Raabe-Menssen C et al. (2004) Effect of aerobic exercise and relaxation training on fatigue and physical performance of cancer patients after surgery. A randomised controlled trial. Support Care Cancer 12 (11): 774-779 55. Granger CL, McDonald CF, Berney S et al. (2011) Exercise intervention to improve exercise capacity and health related quality of life for patients with Non-small cell lung cancer: a systematic review. Lung Cancer 72 (2): 139-153 56. Tessmer G, Zaba O, Grohe C (2011) [Concept for a for - ward-looking communication in the palliative treatment of patients with pneumological-oncological prospec - 65 (8): 503-50957. Bauer KR, Brown M, Cress RD et al. (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive the so-called triple-negative phenotype: a populati - on-based study from the California cancer Registry. Cancer 109 (9): 1721-1728 58. Hudis CA, Gianni L (2011) Triple-negative breast an unmet medical need. Oncologist 16 Suppl 1: 1-11 59. McNeely ML, Campbell K, Ospina M et al. (2010) Exercise interventions for upper-limb dysfunction due to breast can - cer treatment. Cochrane Database Syst Rev (6): CD005211 60. Faller H, Schuler M, Richard M et al. (2013) Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin 61. Arndt V, Stegmaier C, Ziegler H et al. (2008) Quality of life over 5 years in women with breast cancer after breast-con - serving therapy versus mastectomy: a population-based study. J Cancer Res Clin 1311-1318 62. Arndt V, Stegmaier H et al. (2006) A populati - on-based study of the impact of specific symptoms on qua - lity of life in women with breast cancer 1 year after diagnosis. Cancer 107 (10): 2496-2503 63. Arndt V, Merx H, Stegmaier C et al. (2005) Persistence of restrictions in quality of life from the first to the third year after diagnosis in women with breast cancer. J Clin Oncol 23 (22): 4945-4953 64. Arndt V, Stegmaier C, Ziegler H et al. (2006) Living with cancer: Experience from a population-based study of breast cancer survivors five years after diagnosis. In: UICC World Cancer Congress 2006, Washington, DC, USA 65. FATIGUE: PJ, Bellmunt J et al. (2014) EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65 (1): 124-137 72. Boorjian SA, RJ, Rangel LJ et al. (2008) Mayo Clinic validation of the D'amico risk group classification for predic - ting survival following radical prostatectomy. J Urol van Andel G, Bottomley A, Fossa SD et al. (2008) An international field study of the EORTC QLQ-PR25: a questi - onnaire for assessing the health-related quality of life of pati - ents with prostate cancer. Eur J Cancer 44 (16): 2418-2424 75. Wilt TJ, MacDonald R, Rutks I et al. (2008) Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148 (6): 435-448Kapitel 4 Folgen von Krebserkrankungen 171 76. Ravi P, Karakiewicz PI, Roghmann F et al. (2014) Mental health outcomes in elderly men with prostate cancer. Urol Oncol 32 (8): 1333-1340 77. Zenger M, JU et al. (2009) Health-re - lated quality of life of prostate cancer patients compared to the general German population: age-specific results. Urol Int 83 (2): 166-170 78. Neusser S, Lorenz C et al. (2014) [Prostate can - cer in routine healthcare: health-related quality of life after inpatient 1793-1799 79. Eisemann Schnoor M et al. (2015) The ProCaSP study: quality of life outcomes of prostate cancer patients after radiotherapy or radical prostatectomy in a cohort study. BMC Urol 15: 28 80. Mehnert A, Lehmann C, Graefen M et al. (2010) Depression, anxiety, post-traumatic stress disorder and health-related quality of life and its association with social support in am - bulatory prostate cancer patients. Eur J Cancer Care (Engl) 19 736-745 Babjuk M, B\u00f6hle A, Burger M et al. (2016) EAU Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS). Eu - ropean of Urology (Hrsg), Arnhem, Niederlande 84. Witjes JA, Comperat E, Cowan NC et al. (2016) EAU Guide - lines on Muscle-invasive and Metastatic Bladder Cancer. European Association of Urology (Hrsg) 85. Singer S, Ziegler C, Schwalenberg T et al. (2013) Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer. Support Care Cancer 21 (5): 1383-1393 86. Sylvester RJ, van der Meijden AP, Oosterlinck W et al. (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (3): 466-465; discussion 475-467 87. Schmidt S, Frances A, Lorente Garin JA et al. (2015) Quality of life in patients with non-muscle-invasive bladder cancer: one-year results of a multicentre prospective Aaronson NK et al. Validation reliability testing of the EORTC QLQ-NMIBC24 ques - tionnaire module to assess patient-reported Urol 66 (6): 1148-1156 89. Cody JD, Nabi G, Dublin N et al. (2012) Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystec - tomy. Cochrane Database CD003306 90. RE, Abol-Enein H, Davidsson T et al. (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary diversion. AWMF (Hrsg), Berlin 92. Schubert-Fritschle G, Schlesinger-Raab A, Hein R et al. (2013) Quality of life and comorbidity in localized malignant melanoma: results of a German population-based cohort study. Int J Dermatol 52 (6): 693-704 93. Hodi FS, O'Day SJ, McDermott DF et al. (2010) Improved survival with ipilimumab in patients with metastatic mela - noma. The New England journal of medicine 363 (8): 711-723 94. Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The 2507-251695. Winstanley JB, White EG, Boyle FM et (2013) What are the pertinent quality-of-life issues for melanoma cancer patients? Aiming for the development of a new module to accompany the EORTC core questionnaire. Melanoma Res 23 (2): 167-174 96. Winstanley JB, Young TE, Boyle FM et al. (2015) Cross-cultu - ral development of a quality-of-life measure for patients with melanoma: phase 3 testing of an EORTC Melanoma Module. Melanoma 25 (1): 47-58 97. Stang A, Stausberg J, Boedeker W et al. (2008) Nationwide hospitalization costs of skin melanoma and non-melanoma skin cancer in Germany. J Eur 1, In den westlichen Industrie - nationen ist der Fak - pillomviren (HPV) 2. Mutation 1. MutationEpithel Bei nannte Sie ist krankheits\u00fcbergreifend der der und der Spei - ser\u00f6hre und in der Leber [ 71, 72]. Der Konsum von Alkohol um etwa als in der EU insgesamt Hilfe des Mass in Europa w\u00e4re nach den Ergebnissen aus EPIC (European Prospective Investigation into Cancer and Nutrition)-Studien mit einer Verringerung des Krebsrisikos um unterst\u00fctzt je Kind stieg um gut 35 pro Tag, circa 70 die Wirkung k\u00f6rperlicher Aktivit\u00e4t kon and der Vorstufen von Vi - tamin D in der Haut notwendig, das der die vor nichtionisie render Strahlung dem 04. August 2009 das Solarienver - bot f\u00fcr Kinder und Jugendliche eingeteilt. das Herz - kreislaufsystem gibt. noch festgelegt, der allerdings in den letzten Bereich von einem bis 100 Nanometer gesundheitsbeeintr\u00e4chtigenden men. Inzwischen ist 9 bis 14 Jahren > 14 Jahren genannte Niveau von 700 bis Hepatitis B hindeu - ten. Dies ist bei den unter 30-J\u00e4hrigen der Fall. Es Abnahme bei M\u00e4nnern h\u00f6her als bei Frauen. Seit seit erkrank - ten H\u00e4mophiliepatienten, die vor 1987 Blutgerinnungsfakto - ren erhielten, wird mit 80 bis China (3,2%). Das European Centre for Disease Prevention and Control (ECDC) sch\u00e4tzt aufgrund der Pr\u00e4valenz Zunahme den 1960er bis 1980er Jahren zur\u00fcckgef\u00fchrt [ 261]. In Deutsch f\u00fcr - erhielten die Forscher Robin War - ren Marshall 2005 den Nobelpreis f\u00fcr Medizin [275]. Research on Cancer\u00ab (IARC) als Karzinogen mit Literatur 1. International Agency for Research on Cancer (Hrsg) (2014) World Cancer Report 2014. IARC, Lyon Beaglehole R, Bonita R, Horton R et al. (2011) Priority actions for the non-communicable disease crisis. Lancet 377 (9775): 1438-1447 5. Dahlgren G, Whitehead M (1993) Tackling inequalities in health: what can we learn from what has been tried. King\u00b4s Fund, London 6. Kickbusch I, Buckett K (Hrsg) (2010) Implementing Health in All Policies: Adelaide 2010. Department of Health, Gover - nment of South Australia, Adelaide 7. Gesetz vom 17.07.2015 8. World Cancer Research Fund, American Institute for Cancer Research (2009) Policy and Action for Cancer Prevention. Food, Nutrition and Physical Activity: A Global Perspective. AICR, Washington DC 9. Espina C, Miquel P, Sch\u00fcz J et al. (2013) Environmental and occupational interventions for primary prevention of cancer: a cross-sectional policy framework. Environmental Health Perspectives 121 (4): 420-426 10. World Health Organization (2015) Cancer Fact sheet Nr. 297. www.who.int/mediacentre/factsheets/fs297/en/index.html# (Stand: 19.08.2016) 11. Danaei G, Van der Hoorn S, Lopez AD et al. (2005) Causes of cancer in the world: comparative risk assessment of nine behavioural environmental risk factors. Lancet 366 (9499): 1784-1793 12. 13. Anand P, Kunnumakkara AB, Sundaram C et al. (2008) Cancer is a preventable disease that requires major lifestyle changes. Pharmaceutical Research 25 (9): 2097-2116 14. Cogliano VJ, Baan R, Straif K et al. (2011) Preventable exposu - res associated with human cancers. Journal of the National Cancer Institute 103 (24): 1827-1839 15. World Cancer Research Fund, American Institute for Cancer Research (2007) Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective. AICR, Washing - ton DC, www.wcrf.org 16. CM, K (2012) Krebspr\u00e4vention Agency for Research on Cancer (Hrsg) (2012) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. A review of human carcinogens. Part E: Perso - nal habits and indoor combustions. Volume 100 E. IARC, Lyon 21. Verlag Huber, Bern, S 390-398 22. Commission on Social Determinants of Health (2008) Closing the gap in a generation: health equity through action on the social determinants of health. Final Report of the Commission on Social Determinants of Health. World Health Organization (Hrsg), Geneva 23. Wilkinson R, Marmot M (2003) Social determinants of health: The solid facts. 2nd edition. WHO Regional Office for Europe (Hrsg), Copenhagen 24. Rosenbrock R (2001) Was ist New Bundesge - sundheitsbl 44 (8): U, Robra B-P, Schwartz F-W (2012) Pr\u00e4vention. In: Schwartz FW, Walter U, Siegrist J et al. (Hrsg) Public Health Gesundheit und Gesundheitswesen. Urban und Fischer, M\u00fcnchen, S 196-223 27. Rose G (1985) Sick individuals and sick populations. Interna - tional Journal of Epidemiology 14 (1): 32-38 28. Schwartz F, Walter U, Siegrist J et al. (Hrsg) (2012) Public Health. Gesundheit und Gesundheitswesen. Urban und Verlag Hans Huber, (1986) Ottawa-Charta zur Gesundheitsf\u00f6rderung. WHO-autorisierte Hildebrandt/Kickbusch auf Organization (Hrsg) (2009) Interventions on diet and physical activity: what works: summary report. WHO, Geneva 33. Bl\u00fcmel S von 20.07.2016) 39. Craig P, Dieppe P, Macintyre S et al. (2008) Developing and evaluating complex interventions: the new Medical Research Council guidance. Bmj 337: a1655 40. Jordan S (2012) Monitoring 20.06.2016) 44. International Agency for Research on Cancer (1999) Cancer prevention. In: International Agency for Research on Cancer (Hrsg) Cancer Epidemiology: Principles and Methods. WHO/IARC, Lyon, S 355-384 45. WCRF, AICR (2007) Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective. World Cancer Research Fund / American Institute for Cnancer Research (Hrsg), 2, Washington DC 46. Deutsches Krebsforschungszentrum (2015) Die Kosten des Rauchens Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. Mutation Research 567: 447-474 48. U. S. Department of Health and Human Services (2014) The health consequences of smoking-50 years of progress. A re - port of the Surgeon General. USDHHS, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health (Hrsg), Atlanta 49. World Health Organization (Hrsg) (2012) WHO global report: mortality attributable to tobacco. WHO, Geneva 50. Effertz T (2015) Die volkswirtschaftlichen Lang Verlag, Frankfurt am Main 51. Wienecke A, Barnes B, Lampert T et al. (2014) Changes in cancer incidence attributable to tobacco smoking in Germany, 1999 to 2008. International Journal of Cancer 134: 682-691 52. Deutsches Zeiher J, Lampert T (2016) Tabak - Zahlen und Fak Nedela-Morales M et al. (2015) Zur Selbsteinsch\u00e4tzung des Bereit - stellung von Cancer Research Center (eds.) (2011) Ineffecti - veness of the smoking bans in Germany's Restaurants and Bars: A study in 10 Federal States. From Science to Politics. https://www.dkfz.de/de/tabakkontrolle/download/ Publikationen/AdWfP/AdWfP_Ineffectiveness_of_smo 07.07.2016) 68. Joossens L, Raw M (2014) The tobacco control scale 2013 in Europe. Association of European Cancer Leagues (Hrsg), Br\u00fcssel 69. Organisation f\u00fcr wirtschaftliche Zusammenarbeit und Entwicklung (Hrsg) (2014) Health at a 2014. OECD, Paris 70. Deutsches Krebsforschungszentrum, DKFZ, IGKE, Heidelberg, K\u00f6ln 71. Boffetta P, Hashibe M (2006) Alcohol and Cancer. Lancet Oncology 7: 149-156 72. Wight AJ, Ogden GR (1998) Possible mechanisms by which alcohol may influence the development of oral cancer - a review. Oral Oncology 34: L et al. (2010) [Substance use and substance use disorders. Results of the 2009 Epidemiologi - cal Survey of Substance Abuse]. Suchttherapie 56 Morgan A et al. (2012) Social determi - nants of health and well-being among young people. Health Behaviour in School-aged Children (HBSC) study: interna - tional report from the 2009/2010 survey. (Health Policy for Children and Adolescents, No 6). WHO Regional Office for Europe, Copenhagen 77. Effertz T, Bartsch G (2014) Pressemitteilung: 79. Sch\u00fctze M, Boeing H, Pischon T et al. (2011) Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study. Bmj 342: d1584 80. Wienecke A, Barnes B, Neuhauser H et al. (2015) Incident cancers attributable to alcohol consumption in Germany, 2010. Cancer Causes Control 26 (6): 903-911 81. Casswell S et al. (2003) Alcohol: No ordinary commodity. University Press, Oxford 83. B\u00fchler A, Thrul J (2013) (2015) Tackling Harmful Alcohol Use: Economics and Public Health Policy. OECD Publishing. http://dx.doi.org/10.1787/9789264181069-en 85. Babor T, Caetano R, Casswell S et al. (2010) Alcohol: No ordinary commodity. Research and public policy. Second Edition. University Press, Oxford 86. Gesetz \u00fcber al. Anderson P, Baumberg B (2006) Alcohol in Europe. A public health perspective. Institute of Alcohol Studies, UK (Hrsg), London 89. Jugendschutzgesetz (Stand: 19.08.2016) 95. Boeing H Pract H-H (2011) Health burden and costs of obesity and overweight in Germany. European Journal of Health Economics 12: 345-352 97. Lim SS, Vos T, Flaxman AD et al. (2012) A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (9859): 2224-2260 98. World Health Organization (2016) Obesity and overweight. Fact Sheet Nr. 311. http://www.who.int/mediacentre/facts - heets/fs311/en/# (Stand: C, Summerbell C (2011) Evidence-base for primary prevention of obesity in children and adolescents. Bundesgesundheitsbl 54 (3): 259-264 100. Schneider K, Wittig F, Mertens E et al. (2009) Qualitatives Ursache-Wirkungs-Modell SM, Roberts LS, Nomura DK (2013) Mechanisms linking obesity and cancer. Biochemica et Biophysica Acta 1831: 1499-1508 103. Renehan AG, Tyson M, Egger M et al. (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. 371 (9612): 569-578 104. GBM, und Verh\u00e4ltnispr\u00e4 AG, Soerjomataram I, Tyson M et al. (2010) Inci - dent cancer burden attributable to excess body mass index in 30 European countries. International journal of cancer Journal international du cancer 126 (3): 692-702 107. Gonzalez CA, Riboli E (2010) Diet and cancer prevention: Contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. European Journal of Cancer 46: 2555-2562 108. International Agency for Research on Cancer (2015) Q&A on the carcinogenicity of the consumption of red meat and pro - cessed meat. http://www.iarc.fr/en/media-centre/iarcnews/ al. (2015) Carcinoge - nicity of consumption of red and processed meat. Lancet Oncol 16 (16): 1599-1600 110. Deutsche Gesellschaft f\u00fcr GBM, Truthmann J, Rabenberg et Couto E, Wichmann J et al. (2010) Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 102 (8): 529-537 113. Hoffmann K, Boeing H, Volatier J-L et al. (2003) Evaluating the potential health gain of the World Health Organiza - tions\u00b4s recommendation concerning vegetable and fruit consumption. Public Health Nutrition 6 (8): 765-772 114. Eichhorn C, Nagel E Berlin 116. 5 am Tag e.V. am Tag - Die Kampagne. http://www. machmit-5amtag.de/index.php?id=start_machmit (Stand: 19.08.2016) 117. 5 am (Hrsg) Gesundheitsmonitor 2009 Gesundheitsver - - kann vor werden. Pr\u00e4vention Neilson HK, Lynch BM (2010) State of the epidemiological evidence on physical activity and cancer prevention. European Journal of Cancer 46 (14): 2593-2604 124. Steindorf K, Schmidt M, Ulrich Effekte hat Organization (Hrsg) (2010) Global recom - mendations on physical activity for health. WHO, Geneva 127. Krug S, Jordan S, Mensink GBM (7): 840-848 129. Barnes B, Steindorf K, Hein R et al. (2011) Population attributable risk of invasive breast cancer and breast cancer subtypes for modifiable and non-modifiable risk factors. Cancer Epidemiology 35 (4): 345-352 130. Jordan S, Wei\u00df M, Krug S (2013) RP, Lee TK, Bajdik CD et al. (2010) Ultraviolet radiation. Chronic Dis (Suppl Hill D, Auvinen A et al. (2005) Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. Bmj 330 (7485): 223 147. B, Dufey F et al. (2011) The German Uranium Miners Cohort Study (Wismut Cohort) 1946-2003: Technical Report. Bundesamt f\u00fcr Strahlenschutz Organization (Hrsg) (2009) WHO Handbook on indoor radon - a public health perspective. http://apps.who.int/iris/bitstream/10665/44149/1/9789241547673_eng.pdf?ua=1 150. Lim TS, Goh JKH, Mortellaro A et al. CD80 regulate mechanical interactions of T-cells Brunekreef B, Forsberg B (2005) Epidemiological evidence of effects of coarse airborne particles on health. European Respiratory Journal 26 (2): 309-318 152. Eikmann T, Dopp E, Herr C (2010) 153-170 153. World Health Organization (Hrsg) (2006) Air Quality Guide - lines. Global Update 2005. WHO Regional Office for Europe, CopenhagenKapitel 5 Prim\u00e4rpr\u00e4vention von Krebserkrankungen 205 154. Beckers J, 155. Janssen NA, Gerlofs-Nijland ME, Lanki T et al. (2012) Health effects of black carbon. World Health Organization (Hrsg), Copenhagen 156. Wintermeyer D, Kallweit D, Pla\u00df D der (3): 252-254 158. Valavanidis A, Vlachogianni Fiotakis K et al. (2013) Pulmo - nary oxidative stress, inflammation and cancer: Respirable particulate matter, fibrous dusts and ozone as major causes of lung carcinogenesis through reactive oxygen species me - chanisms. International Journal of Environmental Research and Public Health 10 ZJ, Beelen R et al. (2013) Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). The Lancet Oncology 14 (9): 813-822 161. Beelen R, Raaschou-Nielsen O, Stafoggia M et al. (2014) Ef - fects of long-term exposure to air pollution on natural-cause mortality: an analysis of 22 European cohorts within the multicentre ESCAPE project. The Lancet 383 (9919): 785-795 162. Goeckenjan G, Sitter H, Thomas M et (2010) Pr\u00e4vention, Diagnostik, Therapie und Nachsorge des 163. Pope CA, Burnett RT, Thun MJ et al. (2002) Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. Jama 287 (9): 1132-1141 al. (2015) Modelling street level PM10 concentrations across Europe: source appotionment and possible futures. Atmospheric Chemistry and Physics 15: 1539-1553 S 295-305 179. Sockoll I, Kramer I, B\u00f6deker W (2008) land. Gesundheitsberichterstattung des Bundes. Gemein - sam getragen von RKI und Destatis. RKI, Berlin 192. Jablonska S, (2009) Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384 (2): 260-265 195. International Agency for Research on Cancer (Hrsg) (2009) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. A Review of Human Carcinogens. Part B: Biolo - gical K, Howley PM (2002) Human papillomavirus im - mortalization and transformation functions. Virus research 89 (2): 213-228 197. Herfs M, Yamamoto Y, Laury A et al. (2012) A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci USA 109 (26): 10516-10521 198. Herfs M, Vargas S, Yamamoto Y et al. (2013) A novel blueprint for \u00bbtop down\u00ab differentiation defines the cervical squamocolumnar junction during development, reproduc - tive life, and Pathol 199. Mu\u00f1oz N, Bosch F, de Sanjos\u00e9 S et al. (2003) Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Engl J Med 348: 518-527 200. de Sanjose S, Alemany L, Ordi J et al. (2013) Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. European journal of cancer (Oxford, England : 1990) 49 (16): 3450-3461 201. Alemany L, Saunier M, Tinoco L et al. (2014) Large contribu - tion of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. European journal of cancer (Oxford, England : 1990) 50 (16): 2846-2854 202. de Martel C, Ferlay J, Franceschi S et al. (2012) Global bur - den of cancers attributable to infections in 2008: a review and systematic analysis. Lancet Oncology 13 (6): 607-615 203. Winer RL, Lee SK, Hughes JP et al. (2003) Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. American journal of epidemiology 157 (3): 218-226 204. Winer RL, Feng Q, Hughes JP et al. (2008) Risk of female human papillomavirus acquisition associated with first male sex partner. The Journal of infectious diseases 197 (2): 279-282 205. World Health Organization (Hrsg) (2009) Human papillo - mavirus laboratory manual. Immunization, Vaccines and Biologicals. First Edition. WHO, Geneva 206. Bosch FX, Broker TR, Forman D et al. (2013) Comprehensive control of human papillomavirus infections and related diseases. Vaccine 31 Suppl 7: H1-31 207. Petry KU, Luyten A, Justus A et al. (2013) Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84--results of WOLVES, a popula - tion-based epidemiological study in Wolfsburg, Germany. BMC 13: 135 208. Delere Y, Remschmidt C, Leuschner J et al. (2014) Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study Hollwitz B et al. (2007) Prevalence of human papillomavirus types in women screened by cyto - logy in Germany. Journal of medical virology 79 (5): 616-625210. Petry KU, Menton S, Menton M et al. (2003) Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. British journal of cancer 88 (10): 1570-1577 211. Schneider A, Hoyer H, Lotz B et al. (2000) Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. International journal of cancer Journal international du cancer 89 (6): 529-534 212. Giuliano AR, Palefsky JM, Goldstone S (2011) Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 364 (5): 401-411 213. Guan P, Howell-Jones R, Li N et al. (2012) Human papilloma - virus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. International journal of cancer Journal international du cancer 131 (10): 2349-2359 214. Kreimer AR, Bhatia RK, Messeguer AL et al. (2010) Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sexually transmitted diseases 37 (6): 386-391 215. Meyer MF, Huebbers CU, Siefer OG et al. (2014) Prevalence and risk factors for oral human papillomavirus infection in 129 women screened for cervical HPV infection. Oral Oncol 50 (1): 27-31 216. Gillison ML, Broutian T, Pickard RK et al. (2012) Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 217. Schiller JT, Castellsague X, Garland SM (2012) A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30 Suppl 5: F123-138 218. European Medicines Agency (2014) EPAR summary for the public. Cervarix. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000721/WC500024634.pdf (Stand: 31.05.2016) 219. European Medicines Agency for the public. Gardasil. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000703/WC500021146.pdf (Stand: 31.05.2016) 220. T, Feig M, Delere Y et al. (2014) Utilization of admi - nistrative data to assess the association of an adolescent health check-up with human papillomavirus vaccine uptake in Germany. Vaccine 32 (43): 5564-5569 M et al. (2016) Multi - site HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. J Natl Cancer Inst 108 (1) 227. Arnheim-Dahlstrom L, Pasternak B, Svanstrom H et al. (2013) Autoimmune, neurological, and venous thromboem - bolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. 347: 5 228. Grimaldi-Bensouda L, Guillemot D, Godeau B et al. (2014) Autoimmune disorders and quadrivalent human papillo - mavirus vaccination of young female subjects. Journal of internal medicine 275 (4): 398-408 229. Delere Y, Wichmann O, Klug SJ et al. (2014) The efficacy and duration of vaccine protection against human papillo - mavirus: a systematic review and SM, Paavonen J (2012) Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retros - pective pooled 231. JM, Giuliano HPV infection and (2002) Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sexually transmitted diseases 29 CJ, Bleeker MC, van den Brule AJ et al. (2003) Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a rando - mized clinical trial. International journal of cancer Journal international du cancer 107 (5): 811-816 235. Veldhuijzen NJ, Snijders PJ, Reiss P et al. (2010) Factors affecting transmission of mucosal human papillomavirus. Lancet P (1956) [Primary cancer of the liver; critical study of 240 cases]. Revue internationale d'he - patologie 6 (1): 1-86 238. Agency for Research on Cancer (Hrsg) (1994) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Hepatitis Viruses, Hepatitis B (Volume 59). IARC, Lyon 239. Perz JF, Armstrong GL, Farrington LA et al. (2006) The con - tribution of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45 (4): 529-539 240. Berlin 242. Poethko-Muller C, Zimmermann R, Hamouda O et al. (2013) Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Exa - mination Survey for Adults (DEGS1). Bundesgesundheitsbl 56 (5-6): 707-715 243. Cai W, Poethko-Muller C, Hamouda O et al. (2011) Hepatitis B virus infections among children and adolescents in Germany: migration background as a risk factor in a low seroprevalence population. The Pediatric infectious disease journal 30 (1): 19-24 244. Hatzakis A, Van Damme P, Alcorn K et al. (2013) The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. J Viral Hepat 20 (Suppl 2): 1-20 245. European Centre for Disease Prevention and Control (Hrsg) (2010) Surveillance and prevention of hepatitis B and C in Europe. ECDC, Stockholm 246. Rantala M, van de Laar MJ (2008) Surveillance and epide - miology of hepatitis B and C in Europe - a review. Euro sur - veillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 13 (21) 247. European Centre for Disease Prevention and Control (Hrsg) (2014) Hepatitis B and C surveillance in Europe 2012. Table A11. ECDC, Stockholm248. 314-344 249. M (2007) [Vaccina - tion coverage and predictors for vaccination level. Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)]. Bundesgesundheitsbl 50 (5-6): 851-862 251. - gen Infektionskrankheiten in Deutschland - Virushepatitis B, C und D im 2010. Epid Bull 29: 261-271 27-33 254. Alter HJ, Seeff LB (2000) Recovery, persistence, and seque - lae in hepatitis C virus infection: a perspective on long-term outcome. Seminars in liver disease 20 (1): 17-35 255. Krankheiten f\u00fcr 2012. RKI, Berlin 256. International Agency for Research on Cancer (Hrsg) (1994) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Hepatitis Viruses, Hepatitis C (Volume 59). IARC, Lyon f\u00fcr 2015. Hepatitis C. RKI, Berlin 258. European Centre for Disease Prevention and Control (Hrsg) (2013) Hepatitis B and C surveillance in Europe, 2006-2011. ECDC, Stockholm 259. Robert Koch-Institut (Hrsg) (2003) Hepatitis C Gesundheits - berichterstattung des Bundes, Heft 15. RKI, Berlin 260. Koch-Institut (2012) DRUCK-Studie - Drogen Bosetti C, Levi F, Boffetta P et al. (2008) Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepa - tology (Baltimore, Md) 48 (1): 137-145 262. Parkin DM (2006) The global health burden of infection-as - sociated cancers in the year 2002. International Journal of Cancer 118 (12): 3030-3044 263. Razavi H, Waked I, Sarrazin C et al. (2014) The present and future disease burden of hepatitis C virus (HCV) infection with today\u00b4s treatment paradigm. Journal of Viral Hepatitis 21: 34-59 264. Liaw YF, Sung JJ, Chow WC et al. (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (15): 1521-1531 265. Singal AG, Volk ML, Jensen D et al. (2010) A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clinical gast - roenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 8 (3): 280-288, 288.e281 266. Singal AK, Singh A, Jaganmohan S et al. (2010) Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clinical gastroentero - logy and hepatology : the official clinical practice journal of the American Gastroenterological Association 8 (2): 192-199 267. Funk M, 269. Buti M, San Miguel R, Brosa M et al. (2005) Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 42 (5): 639-645 270. Davis GL, Albright JE, Cook SF et al. (2003) Projecting future complications of chronic hepatitis C in the United States. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the Internati - onal Liver Transplantation Society 9 (4): 331-338 271. Deuffic S, Buffat L, Poynard T et al. (1999) Modeling the hepatitis C virus epidemic in France. Hepatology (Baltimore, Md) 29 (5): 1596-1601 272. Perz JF, Alter MJ (2006) The coming wave of HCV-related liver disease: dilemmas and challenges. J Hepatol 44 (3): 441-443 273. Marshall BJ, Warren JR (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1: 1311-1315 274. Warren JR (2006) Helicobacter: the ease and difficulty of a new discovery (Nobel lecture). Chem Med Chem 1 (7): 672-685 275. Nobelprize.org (2016) The Nobel Prize in Physiology or Medicine 2005. Barry J. Marshall and J. Robin Warren. http://www.nobelprize.org/nobel_prizes/medicine/laurea-tes/2005/ (Stand: 20.06.2016) 276. Linz B, Balloux F, Moodley Y et al. (2007) An African origin for the intimate association between humans and Helicob - acter pylori. Nature 444 (7130): York 278. Suerbaum S, Josenhans C (2007) Helicobacter pylori evolution and phenotypic diversification in a changing host. Nature reviews Microbiology 5 (6): 441-452 279. Fischbach W, Malfertheiner P, Hoffmann S3-guidelines \u00bbHelicobacter pylori and gastroduodenal ulcer disease\u00ab for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroentero - logy and nutrition Brenner H (2002) Dynamics of Helicobacter pylori infection in early childhood in a high-risk group living in Germany: loss of infection higher than acquisition. Alimentary pharmacology & 16 (9): Dortschy - (11): 598-603 282. et al. (2007) [Infection with Helicobacter pylori - outcome of a cross-sectional investigation]. Medizinische Wochenschrift 132 (50): 2677-2682 283. Grimm W, W [Helicobacter pylori infection in children and juveniles: an epidemiological study on pre - valence, Medizinische Wochenschrift 284. den Hoed Vila AJ, Holster IL et al. (2011) Helicobacter pylori and the birth cohort effect: evidence for stabilized colonization rates in childhood. Helicobacter 16 (5): 405-409 285. Helicobacter, Cancer Collaborative Group (2001) Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49 (3): 347-353 286. Fischbach LA, Nordenstedt H, J.R. K MN et al. (2012) Helicobac - ter pylori infection and colorectal cancer risk: evidence from a large population-based case-control study in Germany. American journal of epidemiology 175 (5): 441-450 288. Koch M, Meyer TF, Moss SF (2013) Inflammation, immunity, vaccines for Helicobacter pylori infection. Helicobacter 18 (Suppl. 1): 18-23 mographie-Screening-Programms, dem bislang V alle M\u00e4dchen im hei\u00dft bis zum Tag vor Entdeckungsrate ma - und - dieser Art, stark von der Erfahrung und die Details neuen Testverfahrens von vertrags\u00e4rztlichen Kenntnis - einem Alter von 59 Jahren Zunahme der sie 56,6% - die Teilnehmenden verbundenen Komplikationsm\u00f6glichkeiten und Risiken - f\u00fcr Krebsfr\u00fcherkennung 18,5 60,3 45 55,5 50 - 39 40 - 44 13,7 45 - 49 13,8 13,3 50 - Gesetzes und die f\u00fcr bis ie Behandlung ist Sp\u00e4tstadium. f\u00fcr die Entdeckung der Fr\u00fchphase D er Test ist die ie Untersuchungsintervalle den Quali - t\u00e4tsanforderungen der \u00bbEuropean Guidelines for Quality Assurance in Breast Cancer Screening and [ Alter zwischen 50 mit Ausnahme 20 mm 10.542 Stadium bei symptomlosen Frauen im Alter von 50 bis 69 Jahren dar. Die Senkung der Brust - f\u00fchrung Unter der International for Research verbindlichen die Muttermunds und aus dem Geb\u00e4r in der in - land. Gesundheitsberichterstattung des Bundes. Gemein - sam getragen von RKI und Destatis. RKI, Berlin 2. Morrison A (1992) Screening in chronic diesase. 2nd edition. Oxford University Press, New York 3. Spix C, Blettner M (2012) Gordis L (1996) Epidemiology. W. B. Saunders in the causation of human cancers - a brief historical account. Virology 384 (2): 260-265 10. Mu\u00f1oz N, Bosch FX, De Sanjos\u00e9 S et al. (2003) Epidemiolo - gic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine 348 (6): 518-527 11. Krebsinformationsdienst W, Konta B, Peters-Engl (2005) PAP-Test zum Screening auf Zerivixkarzinom. Dokumentation und Information, DIMDI, K\u00f6ln 16. European Commission (2008) European guidelines for qua - lity assurance in cervical cancer screening, Second edition, Luxembourg 17. Gemeinsamer Bundesausschuss 305-34019. Krebsfr\u00fc herkennungs-Richtlinie G\u00f8tzsche PC (2003) Regular self-examination or clinical examination for early detection of breast cancer. Cochrane database of systematic reviews (Online) (2): CD003373 al. (2015) Breast-cancer screening-viewpoint of the IARC working group. New England Journal of Medicine 372 (24): 2353-2358 24. G\u00f8tzsche PC, J\u00f8rgensen KJ (2013) Screening for breast cancer with mammography. The Cochrane database of systematic V. der Stiftung Deutsche Krebshilfe, 2. Auflage, Berlin 27. Moyer VA, Force USPST (2012) Screening for prostate can - cer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157 (2): 120-134 28. Krebsinformationsdienst des 31. Zhu MM, Xu XT, Nie F et al. (2010) Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: A meta-analysis. Journal of Digestive Holleczek B et al. (2016) Decli - ning Bowel Cancer Incidence and Mortality in Germany. Dtsch Arztebl Int 113 (7): 101-106 34. 39. Vogt V, Siegel M, Sundmacher L (2014) Examining regional variation in the use of cancer screening in Germany. Social Science and Medicine 110: 74-80 40. BM (2012) Das - Was es enth\u00e4lt und wie es genutzt werden kann. Public Health Forum 20 (3): 4.e1-4.e3 42. Sa\u00df Deutsches Mammographie-Screening-Programm. Kooperationsgemeinschaft Mammographie, Berlin 45. Loss Kenntnisstand B\u00fchner M et al. (2010) Atti - tude to secondary prevention and concerns about colonos - copy are independent predictors of acceptance of screening colonoscopy. Digestion 81 (2): 120-126 phie-Screening-Programm, 55. Starker Sass Kirschning (2010) Krebsfr\u00fcherken - nung aus Sicht der Public-Health-Ethik. - 61. Katalinic A, Hentschel S, Breitbart EW et (2010) Hand - lungsfeld 1: Weiterentwicklung der Krebsfr\u00fcherkennung. Ziel (Stand: 12.02.2016) - sicherung: Zervixkarzinom. Evidence-based Public Health. Hans Huber Verlag, Bern, S 213-224 65. Wilson J, Jungner (1968) Principles and Practice of Screening for Disease. World Health Organization, Geneva 66. Gemeinsamer Bundesausschuss (2009) Studientypen in Forschung - Teil M, Hoffmann R et (2013) Die erste Welle der Studie zur Gesundheit Erwachsener Broeders M, de Wolf C et al. (Hrsg) (2006) European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth Edition. European Commu - nities, Luxembourg 74. Kooperationsgemeinschaft wesen (2015) und B\u00fcrgerorientierung im Gesundheitswesen G, Tretli S et al. (2013) Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program. Cancer 119 (17): 3106-3112 84. Coldman A, Phillips N, Wilson C et al. (2014) Pan-Canadian study of mammography screening and mortality from breast cancer. Journal of the National Cancer Institute 106 (11) 85. Weedon-Fekjr\u00e6 H, Romundstad PR, Vatten LJ (2014) Mo - dern mammography screening and breast cancer mortality: Population study. BMJ (Online) 348 86. Biller-Andorno N, Ju ni P (2014) Abolishing mammography screening programs? A view from the swiss medical board. New England Journal of Medicine 370 (21): 1965-1967 87. Autier P, Koechlin A, Smans M et al. (2012) Mammography screening and breast cancer mortality in Sweden. Journal of the National Cancer Institute 104 (14): 1080-1093 88. J\u00f8rgensen KJ, Zahl PH, G\u00f8tzsche PC (2010) Breast cancer mortality in organised mammography screening in Den - mark: Comparative study. BMJ (Online) 340 (7750): 797 89. World Health Organization (2015) Cancer. Breast cancer: Arbyn M, Anttila A, Jordan J et al. (2010) European guide - lines for quality assurance in cervical cancer screening. Second edition-summary document. Annals of Oncology 21 (3): 448-458 92. Von Karsa L, Patnick J, Segnan N et al. (2013) European gui - delines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supple - ment publication. Endoscopy 45 (1): 51-59 93. Stacey D, L\u00e9gar\u00e9 F, Col NF et al. (2014) Decision aids for people facing health treatment or screening decisions. The Cochrane database of systematic reviews 1 94. Whitlock Eder M et al. (2011) Screening for Cervical Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville (MD) 102. Klug SJ, Neis KJ, Harlfinger W et trial comparing conventional cytology to liquid-based cytology and computer assistance. International Journal of 132 D, Neuberger Molly M, Djulbegovic M et al. (2013) Screening for prostate cancer. Cochrane Database of Systematic Reviews, http://onlinelibrary.wiley.com/ doi/10.1002/14651858.CD004720.pub3/abstract Buys SS, Partridge E, Black A et al. (2011) Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized control - led trial. JAMA - Journal of the American Medical Association 305 (22): 108. P, Hunger T, al. (2011) Technology (HTA) der Bundesrepublik Deutschland, K\u00f6lnDer Nationale 7 KrebsplanKapitel 7 Krebsfr\u00fcherkennung 240 Kapitel 7 Der Nationale Krebsplan 241 7 Der Nationale Krebsplan Der Nationale Krebsplan (NKP) vier die Har - monisierung der - gabe Am 16. 3]. und - um den Plan auszugestalten und umzusetzen. Darin Zu den Handlungsfeldern 1, 2 und 4 wurden von - 1: Weiterentwicklung der Krebsfr\u00fcherkennung Mit dem 9. April 2013 in Kraft getretenen Gesetz zur bis 54 Jahren, Fr\u00fch - erkennungs-Darmspiegelung ab dem Alter von ten bei vereinbart, Krebsplan Gesellschaft der epidemiologischen Krebsre - gister in Deutschland Steuerungsgruppe gern Februar 2015 in Berlin. In Bezug auf die Krebsfr\u00fcherkennung hat der G-BA - auch mit Blick auf die Umsetzung des KFRG - das f\u00fcr Qua - Gerlach/A. Steckelberg, Uni Hamburg)Kapitel 7 Der Nationale ten, das am 8. Dezember 2015 Kraft getreten ist [ Kommission das Pro - gramm \u00bbEurope Against Cancer\u00ab mit dem \u00fcbergeordneten Ziel, of Registries (ENCR), das heute Bestand hat. Im Jahr die \u00bbEuropean Partnership for Action Against Cancer\u00ab (EPAAC), die 2011 Krebsinformationssystem (European Cancer Information System, der Europ\u00e4ischen Kommission zur Umsetzung dieser Direktive am folgten erster und zweiter Bericht \u00fcber den Stand der Commission mitteilungen/2009/090623_informationspapier_zur_natio - nalen_krebskonferenz.pdf (Stand: 17.08.2016) 3. European Commission (2009) Action Against Cancer: European Partnership. Meeting organized by DG SANCO on the European Partnership for Action Against Mammmakarzinom - C, S (2014) Die in der EU - Gesundheitspolitik und der Beitrag Deutschlands. FORUM 2014 (4): 271-274 30. International Agency Cancer (IARC) 253 31. CANCON Project (2014) Development of the European Guide on Quality Improvement in Comprehensive Cancer Control. https://www.ntnu.edu/prc/cancon pr\u00e4zisere und Europ\u00e4ische seit 1992 die EPIC-Studie [ 15]. In in die Zeitaufwand junger Bereich der Patientenorientierung - beispielsweise der Krebsbehandlung gehen von den onkologischen Spitzenzentren aus, die als Centers (CCC) (Krankenhausstruktur - gesetz - KHSG), das am Kraft Palliativversorgung in Deutschland, Dezember 2015 Kraft getreten ist, werden zentrale An - aufgegriffen 8.6 private Pflege-Pflichtversicherung durchf\u00fchren, die Zusammenarbeit untereinander und mit dem der der Regel die kung angepasstes das den zu Sterbef\u00e4l - len. Der Stand des bewerten Sie Nutzen und Potenziale von Behandlungsleitlinien? (7) Sie Quali - t\u00e4t Gesundheits - bezogene S, Horton R (2014) Research: increasing value, reducing waste. How should medical science change? The Lancet 383: 197-198 9. Moher D, Altman D, Schulz K et al. (2014) Guidelines for Reporting Health Research: A User's Manual. ISBN: 978-0-470-67044-6 10. Shamseer L, Moher D, Clarke M et al. (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRIS - MA-P) 2015: elaboration and Arzneimittelbrief, 46 (49) 12. European Medicines Agency policy on publication of clinical data for medicinal products for human use (EMA/240810/2013) vom 02.10.2014 13. Regulation of the European Parliament and of the Council: Community procedures for the authorisation and supervi - sion of medicinal products for human and veterinary use and establishing a European Medicines Agency ((EC) No 726/2004) vom 31.03.2004, Entwicklungen und globale Herausforderungen, Halle (Saale) 15. European Prospective Investigation into Cancer and Nutri - tion (EPIC) study. http://epic.iarc.fr/ German National Cohort Consortium (2014) The German National Cohort: aims, study design and organization. Eur J Epidemiol 29 (5): 371-382 19. Wichmann HE, Kaaks R, Hoffmann W et (2012) Die Kohorte. Bundesgesundheitsblatt Gesundheits - forschung Gesundheitsschutz trotzdem genau? FORUM 30 (1): 5 24. Institute of Medicine of the National Academies (2011) Clini - cal Practice Guidelines We Can catalog/13058/clinical-practice-guidelines-we-can-trust 25. Kommission Antiinfektiva in Infektionsmedizin in Deutschland 26. Bauer H, Gogol M, Graf-Baumann T et al. (2010) Empfehlun - gen der AWMF zum Umgang mit Nutzerorientierung und Qualit\u00e4t, Berlin 29. Regulation of the European Parliament and of the Council - Clinical trials ( (EU) No 536/2014) Prutsky G, Elraiyah T et al. (2014) Patient engagement in research: a systematic review. BMC Health Services Research 14 (89) 32. Rosenbrock R, Hartung S (2012) Handbuch H, H\u00e4rter M et al. (2011) Nationaler Krebs - plan 4 Patientenorientierung: Lindena G (2015) HOPE Kleinmachnow Gesundheit: Palliativversorgung 55. Van Beek K, Woitha K, Ahmed N et al. (2013) Comparison of legislation, regulations and national health strategies for palliative care in seven European countries (Results from the Europall Research Group): a descriptive study. BMC Health Serv Res 13: 275 56. Nationale Akademie Rossing MA (1996) Healthy Screenee Bias in Epidemiologic Studies of Cancer Incidence. Epidemiology 7 (3): 319-32261. Simbrich A, Wellmann I, Heidrich J et al. (2016) Trends in advanced breast cancer incidence rates after implementa - tion of a mammography screening program in a German population. Cancer Epidemiol 44: 44-51 62. al. (2015) Physical acti - vity, risk of death and recurrence in breast cancer survivors: A systematic review and meta-analysis of epidemiological JA, Heseltine D, Niedzwiecki D et al. (2006) Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. Lonnberg S, Ponti A et al. (2015) Towards better implementation of cancer screening in Europe through im - proved monitoring and evaluation and greater engagement of cancer registries. Eur J Cancer 51 2016 "}